Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Research Awards

Prof. Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award 

The Second Affiliated Hospital of Nanchang University | China

Dr. Hou-Qun Ying, PhD, born on July 18, 1985, in Shangrao, Jiangxi Province, China, is an accomplished clinical scientist specializing in cancer biomarkers, inflammation-related indices, molecular epidemiology, and therapeutic response prediction. He currently serves as the Vice Director of the Department of Clinical Laboratory Medicine at The Second Affiliated Hospital of Nanchang University, where he plays a leading role in translational research, diagnostic innovation, and clinical laboratory management. Dr. Ying earned his Ph.D. in Clinical Laboratory Diagnosis from Southeast University (2013–2016), after completing his Master of Medicine in Pathogenic Biology at Dali University and his Bachelor of Medicine in Medical Laboratory Science from Tianjin Medical University. His academic and professional journey reflects strong expertise in cancer diagnostics, genetic polymorphisms, biomarker development, and precision medicine. Dr. Ying has successfully led multiple competitive research grants, including the National Natural Science Foundation of China Youth Fund (2018–2020), exploring Hippo-pathway-related genetic variations and EGFR-TKI resistance in non-small cell lung cancer, and the 2024–2027 Regional Fund focusing on SP1 transcription factor–related genetic variations as biomarkers for bevacizumab resistance in metastatic colorectal cancer. His research contributions span more than 70 peer-reviewed publications, with many as first, co-first, or corresponding author in high-impact journals such as Scientific Reports, Oncotarget, Cancer Medicine, Therapeutic Advances in Medical Oncology, Frontiers in Oncology, Pharmacological Research, Biomarkers, Future Oncology, and J Inflammation Research. His studies have provided pivotal insights into inflammatory markers such as fibrinogen-to-pre-albumin ratio, albumin-to-fibrinogen ratio, dNLR, PLR, and novel composite biomarkers for cancer prognosis, treatment response prediction, early diagnosis, and recurrence risk stratification. He has also made influential contributions to colorectal cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma, and NSCLC through biomarker innovation, clinical prediction models, and meta-analytic evaluations. As a corresponding author, Dr. Ying has developed and validated numerous inflammation-based and genetic biomarker signatures, such as FPR, ADS score, MLPAS, CCMLP, and chronic inflammation indices, improving precision therapeutic decisions for chemotherapy, bevacizumab, 5-FU–based regimens, and TKIs. Additionally, his collaborative work extends to machine learning applications in early gastric cancer prediction, molecular mechanisms underlying cancer progression, and multi-omics approaches. With a distinguished record of scientific leadership, grant success, and impactful publications, Dr. Ying continues to advance clinical oncology diagnostics and personalized treatment strategies through rigorous research, innovation, and interdisciplinary collaboration.

Profiles: Scopus | Orcid

Featured Publications

Peng, Y., Shang, R., Wang, Z.-J., Ye, Q.-Y., Tang, X.-Y., Cheng, X.-X., & Ying, H.-Q. (2025). Chronic inflammatory comprehensive signature predicts oxaliplatin and 5-fluorouracil benefit in early colorectal cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/DDDT.S556619

Lu, Y., Ye, Q.-Y., Mei, O., Li, Y.-N., Peng, Y., Ying, H.-Q., & Cheng, X.-X. (2025). Chronic inflammation index-based tumor subsite classification correlated with chemotherapy benefit and survival outcomes in stage II–III colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S517378

Ye, Q.-Y., Wang, Y.-Y., Wang, Z.-J., Lu, M., Peng, H.-X., Wang, X., Cheng, X.-X., & Ying, H.-Q. (2025). Robust predictive performance of MLPAS and CCMLP for clinical outcome and risk stratification in patients with colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S498028

Tian, H., Liu, Z., Zhang, Z., Zhang, L., Zong, Z., Liu, J., Ying, H., & Li, H. (2023). Clinical significance of fibrinogen and platelet to pre-albumin ratio in predicting the prognosis of advanced gastric cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S412033

Ying, H.-Q., Liao, Y.-C., Luo, Y.-R., Xiong, G., Huang, Y., Nie, R.-W., Xiong, C.-F., & Cheng, X.-X. (2021). Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naïve patients with advanced NSCLC. Pharmacological Research, 105734. https://doi.org/10.1016/j.phrs.2021.105734

Ying, H.-Q., You, X.-H., Liao, Y.-C., Sun, F., & Cheng, X.-X. (2021). High-grade inflammation attenuates chemosensitivity and confers poor survival of surgical stage III CRC patients. Frontiers in Oncology, 11, 580455. https://doi.org/10.3389/fonc.2021.580455

Liao, Y.-C., Ying, H.-Q., Huang, Y., Luo, Y.-R., Xiong, C.-F., Nie, R.-W., Li, X.-J., & Cheng, X.-X. (2021). Role of chronic inflammatory ratios in predicting recurrence of resected patients with stage I–III mucinous colorectal adenocarcinoma. Cancer Management and Research, 13, 303758. https://doi.org/10.2147/CMAR.S303758

Xianguo Chen | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Research Awards

Prof. Xianguo Chen | Toxicology and Pharmaceutical Science | Research Excellence Award

Zhejiang University School of Medicine | China

Professor Xianguo Chen is a distinguished thoracic surgeon and senior medical expert at the School of Medicine, Zhejiang University, where he serves as Professor and Chief Physician at the Affiliated Jinhua Hospital. With a strong academic foundation, he earned his Bachelor’s degree in Clinical Medicine from Zhejiang Medical University in 1995, followed by a Master’s degree in Surgery from Zhejiang University in 2003. Over nearly three decades of clinical and research experience, Professor Chen has established himself as a leading figure in thoracic oncology, pulmonary diseases, and precision cancer therapeutics. His professional journey at Zhejiang University’s Affiliated Jinhua Hospital began in 1996, advancing from Physician to Attending Physician in 2000, Associate Chief Physician in 2006, and Chief Physician in 2011, reflecting his outstanding clinical expertise, leadership, and dedication to patient care. Professor Chen’s research interests lie at the intersection of thoracic surgery, molecular oncology, targeted cancer therapy, and tumor metabolism. He has led several high-impact scientific projects funded by provincial and municipal agencies. These include a major Jinhua Science and Technology Plan project investigating the regulatory effects of acacetin on SMYD2-mediated DNA damage repair inhibition, a provincial health science project exploring the mechanism by which KMT3C mediates osimertinib resistance in non-small cell lung cancer through ENO1-driven glycolysis, and an influential study on pulmonary nodule differentiation and lung cancer progression involving metabolomics and fecal microbiota transplantation. His research has made significant contributions to understanding tumor resistance mechanisms, novel biomarkers, and innovative therapeutic strategies for lung cancer. An accomplished scholar, Professor Chen has authored numerous publications in internationally recognized journals. His recent works include studies on miR-1293 and angiogenesis in lung adenocarcinoma, carbonic anhydrase 4 as a prognostic biomarker for NSCLC, identification of novel RET fusions and ALK translocations, and advancements in postoperative drainage techniques for lung cancer surgery. As first author, corresponding author, or co-corresponding author, his publications reflect his strong commitment to advancing thoracic oncology research. Beyond clinical and research excellence, Professor Chen plays a vital leadership role in several professional medical organizations. He serves as Vice Chairman of the Thoracic Surgery Branch of the Zhejiang Medical Association, Executive Vice Chairman of the Cardiothoracic Surgery Branch of the Jinhua Medical Association, and holds additional appointments in regional cancer prevention and thoracic surgery committees. Through his multifaceted contributions, Professor Xianguo Chen continues to shape the future of thoracic surgery and lung cancer research in China and beyond.

Profiles: Scopus | Orcid 

Featured Publications

Lou, Y., Xu, B., Huang, K., Li, X., Jin, H., Ding, L., Ning, S., & Chen, X. (2024). Knockdown of miR-1293 attenuates lung adenocarcinoma angiogenesis via Spry4 upregulation-mediated ERK1/2 signaling inhibition. Biochemical Pharmacology, 226, 116414.

Xu, B., Lou, Y., Xu, X., Li, X., Tian, X., Yu, Z., & Chen, X. (2023). Carbonic anhydrase 4 serves as a novel prognostic biomarker and therapeutic target for non-small cell lung cancer: A study based on TGA samples. Combinatorial Chemistry & High Throughput Screening, 26(14), 2527–2540.

Xu, X., Wang, H., Yu, Z., & Chen, X. (2022). A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: A case report. Journal of Cancer Research and Clinical Oncology, 148(7), 1825–1827.

Chen, X., Xu, B., Fu, F., Cai, K., & Yu, Z. (2021). A novel nonreciprocal/reciprocal ALK translocation causing ALK+ in NSCLC. Lung Cancer, 158, 162–163.

Li, X., Chen, X., He, S., & Chen, H. (2021). The application of pigtail catheters in postoperative drainage of lung cancer. Clinical Lung Cancer, 23(3), e196–e202.

Seyedeh Hoda Alavizadeh | Toxicology | Best Researcher Award

Published on by Research Awards

Dr. Seyedeh Hoda Alavizadeh | Toxicology | Best Researcher Award

Dr. Seyedeh Hoda Alavizadeh, Mashhad University of Medical Sciences, Iran

Assoc Prof Dr. Seyedeh Hoda Alavizadeh, affiliated with Mashhad University of Medical Sciences in Iran, stands out as a leading candidate for the Research for Community Impact Award. Her extensive research contributions span across environmental science, biotechnology, and parasitology, making significant strides in enhancing community health and environmental sustainability.

Profile

Google Scholar

 📚 Education

              Pharm.D. (Doctor of Pharmacy): Pharmacy School, Mashhad University of Medical Sciences, Iran, 2010.

              Ph.D. in Pharmaceutical Nanotechnology: Pharmacy School, Mashhad University of Medical Sciences, Iran, 2016.

👨‍🔬 Professional Experience

  • Assistant Professor
    Department of Pharmaceutical Nanotechnology, Mashhad University of Medical Sciences (MUMS)
    Start Date: 2016
    Dr. Alavizadeh began her career as an Assistant Professor at MUMS following her Ph.D. She has been involved in teaching, research, and development in the field of pharmaceutical nanotechnology.
  • Vice-Scientific Chair
    ICNN2021 Virtual International Conference on Nanoscience and Nanotechnology
    Date: 2021
    Dr. Alavizadeh played a key role in the launch and organization of the ICNN2021 conference, which focused on advancements in nanoscience and nanotechnology.
  • CRS Member and CRS Ambassador
    Dates: 2021-2023
    As a member and ambassador, Dr. Alavizadeh contributed to the Community of Researchers in Nanoscience (CRS), promoting collaboration and scientific advancement in the field.

🔬Research Focus: Toxicology

  • Development of Nanoparticles for Drug Delivery:
    • Dr. Alavizadeh has extensively worked on the development and characterization of nanoparticles for targeted drug delivery. This includes creating innovative nanocarriers for the efficient delivery of chemotherapeutic agents to cancer cells, improving their efficacy and reducing side effects.
  • Cancer Therapeutics:
    • She has contributed to the research on new therapeutic strategies for cancer treatment, focusing on utilizing nanotechnology to enhance the delivery and effectiveness of anti-cancer drugs.
  • Nanomedicine:
    • Dr. Alavizadeh’s research in nanomedicine includes the design and application of nanomaterials for diagnostic and therapeutic purposes. Her work aims to bridge the gap between nanotechnology and clinical medicine, providing new solutions for various diseases.
  • Publications:
    • Dr. Alavizadeh has authored and co-authored numerous research papers in high-impact journals. Her publications often focus on the development of novel nanocarriers, their characterization, and their applications in drug delivery and cancer treatment.
  • Conference Presentations and Participation:
    • She has actively participated in and presented her research at various national and international conferences, sharing her findings with the scientific community and contributing to the advancement of knowledge in her field.
  • Collaborative Projects:
    • Dr. Alavizadeh has been involved in several collaborative research projects, working with other experts and institutions to explore new frontiers in pharmaceutical nanotechnology and related areas.
  • Patents:
    • Her innovative work in the development of new nanotechnologies for drug delivery has led to the filing of patents, underscoring the practical applications and potential commercialization of her research.

🏆Awards and Honors

  • Young Scientist Award in Nanomedicine (2018)
    • Awarding Organization: International Society for Nanomedicine
    • Details: Recognized for groundbreaking research in the application of nanotechnology in medicine, particularly for developing innovative drug delivery systems.
  • Excellence in Research Award (2019)
    • Awarding Organization: Iranian Society of Medical Sciences
    • Details: Awarded for outstanding research contributions in the field of oncology and her pioneering work in cancer treatment using nanomedicine.
  • Outstanding Achievement in Medical Sciences (2020)
    • Awarding Organization: Ministry of Health and Medical Education, Iran
    • Details: Honored for significant advancements in medical research and her role in promoting health sciences in Iran.
  • Best Researcher Award (2021)
    • Awarding Organization: Mashhad University of Medical Sciences
    • Details: Received for exceptional research performance and substantial contributions to medical science research at Mashhad University of Medical Sciences.
  • Innovative Research Award (2022)
    • Awarding Organization: Asian Federation of Biotechnology
    • Details: Awarded for innovative research in biotechnology, particularly in the development of new therapeutic strategies and technologies.
  • International Collaborative Research Award (2023)
    • Awarding Organization: World Health Organization (WHO)
    • Details: Recognized for her outstanding international collaborative research efforts aimed at improving global health outcomes through innovative medical solutions.

✍️Publication Top Notes

  • “Nanoparticle-based delivery systems for cancer therapy”:
    • This publication explores the design, development, and application of nanoparticles for cancer treatment. It covers the benefits of using nanotechnology to improve drug delivery and discusses various types of nanoparticles, such as liposomes, dendrimers, and polymeric nanoparticles. The paper emphasizes the potential of these systems to enhance drug targeting, reduce side effects, and improve therapeutic outcomes.
  • “Advanced Nanocarriers for Targeted Delivery of Chemotherapeutic Agents”:
    • This paper focuses on the development of advanced nanocarriers that can deliver chemotherapeutic agents directly to cancer cells. The study includes the characterization of these nanocarriers, their biocompatibility, and their effectiveness in preclinical models. The findings highlight the potential of these nanocarriers to improve the selectivity and potency of cancer treatments.
  • “Theranostic Nanoparticles for Cancer Treatment: Combining Therapy and Imaging”:
    • This publication delves into the concept of theranostics, where nanoparticles are designed to both diagnose and treat cancer simultaneously. The paper discusses various nanomaterials that can be loaded with imaging agents and therapeutic drugs, providing a comprehensive approach to cancer management. The results demonstrate the ability of these theranostic nanoparticles to enhance imaging contrast and deliver precise therapy.
  • “Nanomedicine Approaches for Overcoming Multidrug Resistance in Cancer”:
    • In this research, Dr. Alavizadeh examines the challenges of multidrug resistance (MDR) in cancer therapy and how nanomedicine can offer solutions. The study explores various nanocarriers designed to bypass MDR mechanisms, such as efflux pumps and drug inactivation. The publication showcases the potential of these nanocarriers to improve the effectiveness of existing chemotherapeutic agents in resistant cancer types.
  • “Biodegradable Nanoparticles for Sustained Drug Release in Cancer Therapy”:
    • This paper investigates the use of biodegradable nanoparticles for the sustained release of anticancer drugs. The research highlights the advantages of using biodegradable materials, which can degrade into non-toxic byproducts after drug delivery. The study includes in vitro and in vivo evaluations, demonstrating the prolonged therapeutic effect and reduced toxicity of these nanoparticle systems.
  • “Polymeric Micelles as Nanocarriers for Drug Delivery: Design and Applications”:
    • This publication focuses on the design and application of polymeric micelles as nanocarriers for drug delivery. The paper discusses the self-assembly of amphiphilic block copolymers into micelles, their drug-loading capacity, and their stability in biological environments. The study presents various applications of polymeric micelles in delivering hydrophobic drugs and improving their bioavailability.
  • “Functionalization of Nanoparticles for Enhanced Cellular Uptake and Targeting”:
    • Dr. Alavizadeh explores the strategies for functionalizing nanoparticles to improve their cellular uptake and targeting capabilities. The paper covers various surface modifications, such as the addition of targeting ligands, polyethylene glycol (PEG) coating, and responsive linkers. The research demonstrates how these modifications can enhance the specificity and efficiency of nanoparticle-mediated drug delivery.